Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 7Breast 3Thoracic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 328Lung Neoplasms 158Pancreatic Neoplasms 30Adenocarcinoma of Lung 27Colorectal Neoplasms 26Neoplasms 24Small Cell Lung Carcinoma 21Breast Neoplasms 17Neoplasm Metastasis 15Mesothelioma, Malignant 14Ovarian Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Mesothelioma 10Stomach Neoplasms 9Colonic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Sarcoma 7Prostatic Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Melanoma 6Lymphoma, Non-Hodgkin 6Esophageal Neoplasms 6Lymphoma 5Thoracic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Gemcitabine × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡